이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aspira Women's Health 배당금

배당금 기준 확인 0/6

Aspira Women's Health 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$1.18
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Aspira Women’s Health slips 23% on common stock offering

Aug 22

Aspira Women’s Health GAAP EPS of -$0.07 in-line, revenue of $2.06M misses by $0.34M

Aug 10

Aspira Women's Health Inc.'s (NASDAQ:AWH) Intrinsic Value Is Potentially 69% Above Its Share Price

Jul 06

This Is Why Aspira Women's Health Inc.'s (NASDAQ:AWH) CEO Can Expect A Bump Up In Their Pay Packet

Jun 15

Does Aspira Women's Health (NASDAQ:AWH) Have A Healthy Balance Sheet?

May 19

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 AWH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: AWH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Aspira Women's Health 시장 대비 배당 수익률

AWH 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (AWH)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Medical Equipment)	1.8%
3년 후 애널리스트 예측 (AWH)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 AWH 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 AWH 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 AWH 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: AWH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Aspira Women's Health 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Aspira Women's Health Inc. to Report Q1, 2024 Results on May 15, 2024

Aspira Women's Health Inc. Enhances Its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of Ovawatch

Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024

Consensus revenue estimates decrease by 23%, EPS upgraded

Consensus revenue estimates decrease by 23%, EPS upgraded

Aspira Women's Health Inc., Annual General Meeting, May 13, 2024

Price target decreased by 41% to US$3.30

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Inc. to Report Q4, 2023 Results on Mar 28, 2024

Price target increased by 24% to US$5.60

Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $5.50031 million.

Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors

Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

Consensus revenue estimates decrease by 13%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. to Report Q3, 2023 Results on Nov 13, 2023

High number of new directors

Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

Aspira Women's Health Establishes A New Clinical Advisory Board

Aspira Women’s Health Regains Nasdaq Compliance

Aspira Women’s Health Announces Executive Changes

Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations

Consensus EPS estimates upgraded to US$2.13 loss, revenue downgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women’S Health Inc. Announces Resignation of Ryan Phan as Chief Scientific and Operating Officer, Effective September 15, 2023

Aspira Women's Health Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Share price stability

Aspira Women’s Health Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors, Member of Nominating and Corporate Governance Committee

Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors

High number of new and inexperienced directors

Consensus revenue estimates decrease by 13%

Aspira Women's Health Inc. Announces Chief Financial Officer Changes, Effective June 15, 2023

First quarter 2023 earnings released: US$0.73 loss per share (vs US$1.24 loss in 1Q 2022)

Aspira Women's Health Inc. Appoints Three New Members to Its Board of Directors

Full year 2022 earnings: EPS exceeds analyst expectations

Aspira Women’s Health Inc. Announces Publication of Real-World Data Validating Use of OvaWatch for Management of Adnexal Masses

Aspira Women's Health Inc. Announces Executive Changes

Aspira Women's Health Receives A Written Notice from Nasdaq

Aspira Women's Health Inc. Announces the Commercial Launch of OvaWatch

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Aspira Women's Health Inc. to Report Q3, 2022 Results on Nov 10, 2022

Aspira Women's Health Inc. Announces Publication of Its Second-Generation Multivariate Index Assay, Overa®, in the Detection of Cancer in Filipino Women

Aspira Women's Health Inc. has completed a Follow-on Equity Offering.

Aspira Women’s Health slips 23% on common stock offering

Consensus forecasts updated

Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.063 loss in 2Q 2021)

Aspira Women’s Health GAAP EPS of -$0.07 in-line, revenue of $2.06M misses by $0.34M

Is Aspira Women's Health (NASDAQ:AWH) Using Too Much Debt?

Aspira Women's Health Inc. to Report Q2, 2022 Results on Aug 10, 2022

Aspira Women's Health Inc. Announces Board Appointments

Aspira Women’s Health Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

President recently bought US$75k worth of stock

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Aspira Women's Health Inc. Appoints Ryan Phan, Ph.D. as Chief Operating and Scientific Officer

Aspira Women's Health Inc., Annual General Meeting, Jun 23, 2022

Price target decreased to US$4.00

Is Aspira Women's Health (NASDAQ:AWH) Weighed On By Its Debt Load?

Consensus forecasts updated

High number of new directors

Aspira Women's Health Inc. Appoints Valerie B. Palmieri as Its Executive Chairperson

Aspira Women’S Health Announces Appointment of Celeste Fralick to Its Board of Directors

Aspira Women's Health Inc. Appoints Nicole Sandford as Chief Executive Officer, Effective March 1, 2022

Aspira Women’s Health, Inc. Name Mr. Michael Newton as Head of Sales and Marketing

Health Check: How Prudently Does Aspira Women's Health (NASDAQ:AWH) Use Debt?

Consensus EPS estimates fall to -US$0.30

Third quarter 2021 earnings released: US$0.087 loss per share (vs US$0.042 loss in 3Q 2020)

Aspira Women's Health (NASDAQ:AWH) Has Debt But No Earnings; Should You Worry?